JaLCDOI | 10.18926/AMO/54603 |
---|---|
FullText URL | 70_5_409.pdf |
Author | Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune| |
Abstract | Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD. |
Keywords | Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD |
Amo Type | Clinical Study Protocols |
Publication Title | Acta Medica Okayama |
Published Date | 2016-10 |
Volume | volume70 |
Issue | issue5 |
Publisher | Okayama University Medical School |
Start Page | 409 |
End Page | 412 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 27777437 |
Web of Science KeyUT | 000388098700014 |
Title Alternative | An investigator initiated phase II clinical trial of tamibarotene (AM80G) for chronic graft-versus-host disease |
---|---|
FullText URL | 127_133.pdf |
Author | Nishimori, Hisakazu| Maeda, Yoshinobu| |
Keywords | 臨床研究中核病院 慢性GVHD タミバロテン 同種造血幹細胞移植 Th17 |
Publication Title | 岡山医学会雑誌 |
Published Date | 2015-08-03 |
Volume | volume127 |
Issue | issue2 |
Start Page | 133 |
End Page | 137 |
ISSN | 0030-1558 |
Related Url | isVersionOf https://doi.org/10.4044/joma.127.133 |
language | Japanese |
Copyright Holders | Copyright (c) 2015 岡山医学会 |
File Version | publisher |
DOI | 10.4044/joma.127.133 |
NAID | 130005096255 |
Author | Sugiyama, Haruko| Maeda, Yoshinobu| Nishimori, Hisakazu| Yamasuji, Yoshiko| Matsuoka, Ken-ichi| Fujii, Nobuharu| Kondo, Eisei| Shinagawa, Katsuji| Tanaka, Takehiro| Takeuchi, Kengo| Teshima, Takanori| Tanimoto, Mitsune| |
---|---|
Published Date | 2014-02 |
Publication Title | Biology of Blood and Marrow Transplantation |
Volume | volume20 |
Issue | issue2 |
Content Type | Journal Article |
Author | Kurimoto, Etsuko| Miyahara, Nobuaki| Kanehiro, Arihiko| Waseda, Koichi| Taniguchi, Akihiko| Ikeda, Genyo| Koga, Hikari| Nishimori, Hisakazu| Tanimoto, Yasushi| Kataoka, Mikio| Iwakura, Yoichiro| Gelfand, Erwin W.| Tanimoto, Mitsune| |
---|---|
Published Date | 2013-01-20 |
Publication Title | Respiratory Research |
Volume | volume14 |
Content Type | Journal Article |
Title Alternative | Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophages |
---|---|
FullText URL | 126_1.pdf |
Author | Miyamoto, Satoshi| Shikata, Kenichi| Miyasaka, Kyoko| Okada, Shinichi| Sasaki, Motofumi| Kodera, Ryo| Hirota, Daisho| Kajitani, Nobuo| Takatsuka, Tetsuharu| Kataoka Usui, Hitomi| Nishishita, Shingo| Horiguchi Sato, Chikage| Funakoshi, Akihiro| Nishimori, Hisakazu| Uchida, Haruhito Adam| Ogawa, Daisuke| Makino, Hirofumi| |
Keywords | cholecystokinin 糖尿病性腎症 抗炎症作用 腎保護効果 |
Publication Title | 岡山医学会雑誌 |
Published Date | 2014-04-01 |
Volume | volume126 |
Issue | issue1 |
Start Page | 1 |
End Page | 6 |
ISSN | 0030-1558 |
Related Url | http://www.okayama-u.ac.jp/user/oma/ |
language | Japanese |
Copyright Holders | Copyright (c) 2014 岡山医学会 |
File Version | publisher |
DOI | 10.4044/joma.126.1 |
JaLCDOI | 10.18926/AMO/49251 |
---|---|
FullText URL | 67_1_1.pdf |
Author | Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune| |
Abstract | Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th17 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment. |
Keywords | chronic GVHD Th17 Am80 regulatory T cell (Treg) steroid-refractory |
Amo Type | Review |
Publication Title | Acta Medica Okayama |
Published Date | 2013-02 |
Volume | volume67 |
Issue | issue1 |
Publisher | Okayama University Medical School |
Start Page | 1 |
End Page | 8 |
ISSN | 0386-300X |
NCID | AA00508441 |
Content Type | Journal Article |
language | English |
Copyright Holders | CopyrightⒸ 2013 by Okayama University Medical School |
File Version | publisher |
Refereed | True |
PubMed ID | 23439503 |
Web of Science KeyUT | 000316829900001 |
Author | Nishimori, Hisakazu| Maeda, Yoshinobu| Tanimoto, Mitsune| |
---|---|
Published Date | 2012-12-03 |
Publication Title | 岡山医学会雑誌 |
Volume | volume124 |
Issue | issue3 |
Content Type | Journal Article |